Lisanti Capital Growth LLC lessened its holdings in shares of Penumbra Inc (NYSE:PEN) by 52.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,965 shares of the company’s stock after selling 12,181 shares during the period. Lisanti Capital Growth LLC’s holdings in Penumbra were worth $1,641,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Advisors Preferred LLC grew its stake in Penumbra by 40.1% during the 2nd quarter. Advisors Preferred LLC now owns 1,220 shares of the company’s stock valued at $169,000 after acquiring an additional 349 shares in the last quarter. BlueMountain Capital Management LLC purchased a new stake in Penumbra during the 2nd quarter valued at about $267,000. NumerixS Investment Technologies Inc grew its stake in Penumbra by 20.0% during the 2nd quarter. NumerixS Investment Technologies Inc now owns 2,520 shares of the company’s stock valued at $354,000 after acquiring an additional 420 shares in the last quarter. Leavell Investment Management Inc. grew its stake in Penumbra by 35.0% during the 2nd quarter. Leavell Investment Management Inc. now owns 2,700 shares of the company’s stock valued at $373,000 after acquiring an additional 700 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC purchased a new stake in Penumbra during the 2nd quarter valued at about $387,000. 74.33% of the stock is owned by institutional investors.
NYSE:PEN opened at $155.58 on Friday. The stock has a market capitalization of $5.10 billion, a price-to-earnings ratio of -15,558.00, a PEG ratio of 21.72 and a beta of 0.41. Penumbra Inc has a 1-year low of $82.55 and a 1-year high of $167.35.
PEN has been the subject of several research reports. ValuEngine cut shares of Penumbra from a “buy” rating to a “hold” rating in a research note on Wednesday, August 8th. BMO Capital Markets upped their price objective on shares of Penumbra from $140.00 to $150.00 and gave the company a “market perform” rating in a research note on Thursday, August 9th. Zacks Investment Research raised shares of Penumbra from a “hold” rating to a “strong-buy” rating and set a $143.00 price objective for the company in a research note on Saturday, August 11th. Canaccord Genuity reaffirmed a “buy” rating and set a $175.00 price objective on shares of Penumbra in a research note on Monday, August 20th. Finally, TheStreet raised shares of Penumbra from a “d+” rating to a “c” rating in a research note on Monday, September 17th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Penumbra has an average rating of “Buy” and a consensus target price of $145.57.
In other Penumbra news, EVP Robert D. Evans sold 3,000 shares of the business’s stock in a transaction dated Thursday, August 30th. The shares were sold at an average price of $135.08, for a total value of $405,240.00. Following the transaction, the executive vice president now directly owns 16,296 shares in the company, valued at approximately $2,201,263.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Harpreet Grewal sold 665 shares of the business’s stock in a transaction dated Tuesday, October 2nd. The shares were sold at an average price of $148.58, for a total transaction of $98,805.70. The disclosure for this sale can be found here. Insiders sold a total of 30,518 shares of company stock worth $4,003,618 over the last quarter. 10.70% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: “Lisanti Capital Growth LLC Reduces Position in Penumbra Inc (PEN)” was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://sportsperspectives.com/2018/11/09/lisanti-capital-growth-llc-reduces-position-in-penumbra-inc-pen.html.
Penumbra, Inc designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands.
Recommended Story: Why do companies engage in swaps?
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.